In human patients with non-small cell lung cancer (NSCLC), TIM-3 is predominantly expressed in tumor-infiltrating CD4+ and CD8+ T cells, but expressed at minimal levels on T cells from peripheral blood. Here, CD8A is linked to neoplasm.